Plantibodies
Plantibodies specializes in innovative oral biologic delivery solutions, focusing on colon-targeted biologics for gastrointestinal diseases. Their proprietary platform enables rapid, safe, and precise delivery of biologics directly to the gut, enhancing efficacy and safety. They aim to expand pipelines with non-systemic, oral assets and are actively seeking strategic partnerships to co-develop and demonstrate differentiated delivery for gut-localized indications.
Industries
Nr. of Employees
small (1-50)
Plantibodies
Products
Colon-targeted oral biologic programs for inflammatory bowel disease (IBD)
Preclinical programs developing orally administered biologics aimed at local treatment of Crohn’s disease and ulcerative colitis to reduce systemic exposure and improve local efficacy.
Colon-targeted oral biologic programs for MSI-H colorectal cancer
Programs exploring local modulation of the tumor microenvironment in microsatellite instability-high colorectal cancer using orally delivered biologics to improve efficacy and reduce systemic side effects.
Preclinical program for rare and orphan GI diseases (partnered)
Joint preclinical development with an external partner targeting an undisclosed rare gastrointestinal disorder where local biologic delivery may provide therapeutic benefit.
Colon-targeted oral biologic programs for inflammatory bowel disease (IBD)
Preclinical programs developing orally administered biologics aimed at local treatment of Crohn’s disease and ulcerative colitis to reduce systemic exposure and improve local efficacy.
Colon-targeted oral biologic programs for MSI-H colorectal cancer
Programs exploring local modulation of the tumor microenvironment in microsatellite instability-high colorectal cancer using orally delivered biologics to improve efficacy and reduce systemic side effects.
Preclinical program for rare and orphan GI diseases (partnered)
Joint preclinical development with an external partner targeting an undisclosed rare gastrointestinal disorder where local biologic delivery may provide therapeutic benefit.
Services
Discovery Pilot
Rodent-scale proof-of-concept batches formulated as oral-ready powder for colon release; intended to support early in vivo studies.
Preclinical Core
Multi-study batch production in the 500 mg–2 g range, formulated for oral administration and colonic release to support multiple preclinical studies.
Extended Batch
Large-animal and toxicology-scale batch production (5–10 g) to support tox and large-animal studies.
Platform Access
Ongoing access to the delivery platform for multiple candidates and repeat batches to support pipeline expansion or partnered programs.
Discovery Pilot
Rodent-scale proof-of-concept batches formulated as oral-ready powder for colon release; intended to support early in vivo studies.
Preclinical Core
Multi-study batch production in the 500 mg–2 g range, formulated for oral administration and colonic release to support multiple preclinical studies.
Extended Batch
Large-animal and toxicology-scale batch production (5–10 g) to support tox and large-animal studies.
Platform Access
Ongoing access to the delivery platform for multiple candidates and repeat batches to support pipeline expansion or partnered programs.
Expertise Areas
- Colon-targeted oral biologic delivery
- Oral formulation and bioencapsulation using natural polymers
- Preclinical development and in vivo validation for GI delivery
- Formulation scale-up for rodent and large-animal/tox studies
Key Technologies
- Natural fiber-based bioencapsulation
- Colon-release oral powder formulation
- Plant-based biologics production methods
- In vivo preclinical models for GI delivery and target engagement